Hypertension

Living Kidney Donor Outcomes Vary by Race

Jody A. Charnow August 19, 2010

Black and Hispanic living kidney donors are at increased relative risk for hypertension, diabetes requiring drug therapy, and CKD compared with their white counterparts, according to researchers.
 

Report: Data Do Not Justify Advised BP Goals in CKD

Delicia Honen Yard August 19, 2010

The target BP level of less than 130/80 mm Hg for CKD patients—which is recommended by a Kidney Disease Outcomes Quality Initiative guideline—is not definitively supported by scientific data and could potentially lead to adverse effects, according to Julia B. Lewis, MD, of the division of nephrology and hypertension at Vanderbilt University School of Medicine in Nashville.
 

Electronic Records May Help Improve BP Control

John Schieszer July 28, 2010

NEW YORK—New findings suggest that electronic health records (EHR) with special features for managing hypertension may be highly beneficial in improving BP control.
 

Studies Support Earlier Intervention

John Schieszer July 27, 2010

Doctors may be able to head off ESRD and CVD by treating pre-diabetes and pre-hypertension sooner.
 

BP Lowering Better with a Triple Regimen

John Schieszer July 12, 2010

NEW YORK—An investigational triple regimen of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) may result in significantly greater mean reductions in BP compared with a combination of any two of these drugs in patients with moderate to severe hypertension, new data show.
 

Increased Hypertension Risk Found in Live Kidney Donors

Jody A. Charnow June 26, 2010

MUNICH, GERMANY—Live kidney donors may experience an increase in blood pressure following nephrectomy, new data suggest.
 

BP Guidelines May be Inappropriate for HD Patients

John Schieszer May 21, 2010

SEATTLE—Guidelines recommend that hemodialysis (HD) patients have predialysis BP levels below 140/90 mm Hg, but study findings suggest that such levels may increase their risk of death, according to David Goodkin, MD, an investigator with Arbor Research Collaborative for Health.
 

New Formulation of PAH Medication Is Now Available

Jody A. Charnow May 21, 2010

Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, is now commercially available, according to the drug's maker, Actelion Pharmaceuticals US, Inc., of South San Francisco, Calif.
 

Olmesartan Cleared for Treating Hypertension in Children

Jody A. Charnow March 30, 2010

The FDA approved the use of Benicar (olmesartan medoxomil) for the treatment of hypertension in individuals aged 6 to 16 years. The drug original was cleared in 2002 for the treatment of adult hypertension.
 

Resistant Hypertension Tied to Less Sleep

Jody A. Charnow March 30, 2010

Short sleep time and poor sleep efficiency may have an etiologic role.
 
Visit our Conference Highlights section for news from recent meetings, including our coverage of the American Transplant Congress.

Your Money

Visit Your Money for the latest financial news and advice.
Stay up to date on the latest Legal Issues affecting urologists and nephrologists.
Our World Literature Review department has information on the latest nephrology and urology studies from around the world.

Renal & Urology News
E-Newsletters

Sign up today to start receiving one of three free e-newsletters from Renal & Urology News or get them all.
- eTOC (print edition preview)
- RUN Roundup
- Conference Highlights

Sample | Subscribe | Archive


This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions